Comparative in-vitro activity of CP-99219, a new quinolone, against respiratory pathogens

Abstract

The comparative in-vitro activity of CP-99219, a new quinolone, against Haemophilus influenzae (150 isolates), Moraxella catarrhalis (100), Streptococcus pneumoniae (80) and Group A beta-haemolytic streptococci (40) was determined using an agar dilution technique. CP-99219 was the most active compound tested against M. catarrhalis (MIC50 = 0.015 mg/L, MIC90 = 0.03 mg/L). Ceftriaxone, CP-99219 and ciprofloxacin were the three most active agents tested against H.influenzae. CP-99219 showed good activity, 16-fold greater than that of ciprofloxacin, against S.pneumoniae (MIC50 = 0.12 mg/L; MIC90 = 0.25 mg/L) and was also active against Group A streptococci. Clinical studies regarding the use of CP-99219 in respiratory tract infections seem indicated.

Pharmacodynamics of Trovafloxacin, Ofloxacin, and Ciprofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model

“…Trovafloxacin is a new fluoroquinolone that exhibits enhanced potency against S. pneumoniae. In comparisons with ciprofloxacin and ofloxacin, trovafloxacin is generally 8-to 16-fold more potent, with MICs at which 90% of the isolates are inhibited of 0.12 to 0.25 g/ml (27,33,40). The purpose of this study was to compare the in vitro pharmacodynamics of trovafloxacin with those of ofloxacin and ciprofloxacin against S. pneumoniae and to determine if trovafloxacin's enhanced potency would translate to enhanced pharmacodynamic killing when serum pharmacokinetics were simulated.…”

Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones

“…Trovafloxacin has comparable activity to ciprofloxacin against H. influenzae and Moraxella catarrhalis , and improved activity against Streptococcus pneumoniae and group A streptococci [40]. In addition, it is highly active against Legionella spp.…”